Ocuphire Pharma, Inc. (Nasdaq: OCUP)

ABOUT: Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company’s pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size is in late stage  clinical development for 3 indications: Reversal of Mydriasis, Presbyopia, and Night Vision Disturbances.  Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal diseases, such as diabetic retinopathy and diabetic macular edema. The company has 3 more  data readouts across  Phase 3 and Phase 2 trials over the next 12 months, with one recent positive Phase 3 data readout for Nyxol.

Interview update with Mina Sooch, CEO


About The Wall Street Analyzer 1515 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.